Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Well Corp (AMWL) vs Merck & Co., Inc. (MRK) Price & Performance

American Well CorpTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

American Well Corp vs Merck & Co., Inc. — how do they compare? American Well Corp trades at $13.01 (market cap $220.94M), while Merck & Co., Inc. trades at $133.14 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 1456.4× American Well Corp's market cap, and Merck & Co., Inc. pays a 2.61% dividend while American Well Corp pays none. Which is the better fit depends on your goals.

AMWLMRK
Market Cap
$220.94M$321.77B
Sector
HealthHealth
52-Week High
$13.58$131.84
52-Week Low
$3.78$77.60
Enterprise Value
$27.98M$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Well Corp

AMWL trades at $12.54, down 7.66% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving financial trends, with revenue declining to $249.33M in 2025 but net losses narrowing significantly to -$95.70M. Recent Q2 2026 earnings beat expectations, and news highlights strategic developments including a key executive appointment at Amazon's healthcare unit.

The outlook suggests cautious optimism as AMWL progresses toward cash-flow breakeven, supported by analyst coverage leaning Hold. Key risks include persistent revenue declines and high cash burn, though improving margins and reduced losses indicate potential for recovery if execution continues.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Well Corp

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.

Read more on AMWL

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK